Company Filing History:
1 out of 832,761 Years Active: 2023
Title: Elodie Petitjean: Innovator in Drug Safety
Introduction
Elodie Petitjean is a notable inventor based in Senlis, France. She has made significant contributions to the field of drug safety, particularly in addressing the risks associated with drug-induced QT interval prolongation. Her innovative approach has the potential to enhance patient safety during drug administration.
Latest Patents
Elodie Petitjean holds a patent titled "Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of mitochondrial origin." This patent outlines a method for treating subjects to reduce the risk of QT space prolongation associated with the intake of drugs known to prolong QT space. The method includes administering at least one specific inhibitor of mitochondrial ROS production, such as anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, alongside the drug known to prolong QT space. She has 1 patent to her name.
Career Highlights
Throughout her career, Elodie has focused on developing innovative solutions to improve drug safety. Her work has garnered attention in the pharmaceutical industry, highlighting her commitment to advancing medical research and patient care.
Collaborations
Elodie collaborates with notable individuals in her field, including Olivier Petitjean and Guillaume Petitjean. These partnerships enhance her research and contribute to the development of effective solutions in drug safety.
Conclusion
Elodie Petitjean is a pioneering inventor whose work in drug safety is making a significant impact. Her innovative methods for preventing drug-induced QT interval prolongation demonstrate her dedication to improving patient outcomes.